test 6 part 2 Flashcards
What Happens When An Arterial Blood Vessel Is Damaged?
Vascular constriction Platelet adhesion Platelet activation formation of the platelet plug Activation of cell-based coagulation formation of fibrin clot Clot retraction Activation of fibrinolytic cascade Vessel repair / regeneration
Vascular Constriction
Seen when blood vessel itself is injured
persistent constriction of the smooth muscles (only the smaller vessels)
Most prominent following severe crushing type
injuries (rather than a slicing wound)
Constriction requires the presence of smooth
muscle fibers!!
Platelet Adhesion - PROBLEM
Shear stress along vessel wall
Shear stress inversely related to flow velocity
Shear stress Values at vessel wall: 500/sec larger arteries; 5,000/sec arterioles (huge amount of shear stress at the wall of each vessel)
Opposes any tendency of FLOWING BLOOD to clot
limits time available for procoagulant reactions to occur
displaces cells or proteins not tightly bound to the vessel wall
GOOD NEWS: platelets pushed to vessel perimeter by larger erythrocytes & leukocytes (coaxial migration)
Platelet Adhesion – vWf, GPIb Interaction
Adhesion must occur very rapidly – i.e. instantaneously
“Capture” depends on several binding sites
subendothelial molecules of von Willebrand’s factor (vWf) and collagen
platelet surface receptor called Glycoprotein Ib (GPIb)
vWf held in place by binding to subendothelial collagen
GPIb binds easily with vWf, but it is a low-affinity interaction - - Slows, but does not stop the platelet —tumbles slowly over endothelium
-two steps: 1. slows them down.
-2. forms stronger bond
to stop the platelet in place
-high attraction with low affinity
Interaction between platelet GPIb and the vWf molecule causes transmembrane signaling
Transmembrane signaling coupled with high shear stress results in activation of the platelet
Platelet Activation
Platelet loses normal discoid shape
Platelet receptor GPIIb/IIIa undergoes conformational change and becomes active and is now able to bind to the vWf
GPIIb/IIIa (glycoprotein) now able to bind to another binding site on vWf (GPIIb/IIIa site of action of newer antiplatelet agents)
high-affinity bond that secures activated platelet to subendothelium
Subendothelial collagen binds with platelet receptor GPIa/IIa
at medium shear stress strong enough to bind platelet to subendothelium
Subendothelial collagen also binds with platelet receptor GPIV which causes activation of the platelet
Simplified version of platelet activation
1) GPIb binds with vWf = initial activation
2) GPIIb/IIIa binds with vWf = holder
3) GPIa/IIa binds with subendothelial collagen = holder
4) GPIV binds with collagen = continues enhancing activation process (additional transmembrane signaling)
Platelet Activation - Goals
Recruitment of additional platelets
Vasoconstriction of smaller arteries
Local release of ligands needed for stable platelet-platelet matrix
Localization and acceleration of platelet-associated
fibrin formation
Protection of clot from fibrinolysis
Recruitment of Additional Platelets: activated platelets agonists (3)
Thromboxane A2
(TXA2) important platelet agonist and vasoconstrictor
formed in cytosol following cyclooxygenase cleavage of arachidonic acid
cyclooxygenase activity irreversibly inhibited by aspirin – no TXA2 formation (platelets don’t get produced)
Serotonin released from platelet granules - platelet agonist and vasoconstrictor
Adenosine diphosphate (ADP) released from platelet granules - platelet agonist no known vasoactive role
Formation of Platelet Plug
Surface receptor GPIIb/IIIa undergoes calcium dependent conformational change
able to bind with fibrinogen or vWf
Fibrinogen and vWf stored in alpha-granules within platelet – released following activation
Fibrinogen and vWf bonds form between platelets binding them together in a tight matrix
More than 50,000 GPIIb/IIIa receptors present on platelet surface – additional receptor molecules available within cytoplasm (ensures very good binding between the platelets => very strong platelet plug)
Termination Phase of Clot Formation
Even as the fibrin clot is forming, the Termination system (Fibrinolysis) is being initiated
Fibrinolysis will disrupt the clotting process and the clot itself
Four naturally occurring anticoagulants help control the spread of coagulation activation
Tissue Factor Pathway Inhibitor (TFPI)
Protein C (PC)
Protein S (PS)
Antithrombin III (AT or ATIII)
Tissue Factor Pathway Inhibitor
-Forms a four part complex:
TF/VIIa/Xa/TFPI
-Result:
Inactivates the factors and inhibits formation of the “priming” dose of thrombin which inhibits coagulation process
Protein C & Protein S
Both inactivate Va and VIIIa
- can’t convert prothrombin to thrombin
- concentration driven
Protein C
It is a vitamin K-dependent plasma glycoprotein
-formed by the liver
Helps break down Va VIIIa
It is activated by thrombin
Negative feedback loop??
-as [thrombin] goes up, an [anticoagulant] (protein C) goes up
Overall activity increased by Protein S
Protein S is also vitamin K-dependent
Antithrombin III
Inhibits the action of thrombin Inhibits action of other serine proteases IXa Xa XIa XIIa
Fibrinolysis
The production of plasmin signals the fibrinolytic phase of coagulation
Plasmin is produced from
- plasminogen (zymogen)
Plasmin is produced from
plasminogen (zymogen) by
the action of
Urokinase-type plasminogen activator (uPA)
Tissue -type plasminogen activator (tPA)
Released by endothelial cells
Activated by thrombin (negative feedback??) and venous occlusion
-Factor XIa, XIIa, and Kallikrein
Action of Fibrinolysis
tPA and plasminogen bind to growing fibrin polymer as fibrinogen (I) is converted to
fibrin (Ia)
Plasminogen is activated to plasmin which cleaved fibrin strands
Cleaved fibrin produces Fibrin Degradation Products (FDPs or Fibrin Split Products)
FDPs are measured to help determine amount of fibrinolysis that is occuring
Endogenous Anticoagulants
Prevent clotting – keep blood liquid
Require intact endothelial cell barrier (minimize tissue factor bearing receptors)
Arterial vessels
velocity of blood flow
endothelial cells negative charge repels platelets
endothelial release of nitric oxide (endothelium-derived relaxant factor) & prostacyclin (PGI2 ) – inhibit platelet adhesion and aggregation
endothelial release of ADPase – inactivates platelet released ADP limiting ability to recruit other platelets
Anytime you activate something, what happens
- everything else becomes activated
What effect does coagulation have on cardiac surgery and cardiopulmonary bypass?
Bleeding
bad outcome; increased cost; increased exposure to blood products; increased chance of infection
Circuit integrity
large foreign surface stimulates coagulation cascade; concerned with coagulation monitoring / treatment of circuit surface / protocols
Inflammation
coagulation cascade will stimulate inflammation activities
Disease state of patient
what patient conditions will affect coagulation status?
diabetes; liver disease; obesity
Effect of Bypass/Surgery on Coagulation
Activates intrinsic and extrinsic coagulation pathways
large negatively charged surface: activates intrinsic pathway
coronary suction: activates extrinsic pathway by introducing tissue factor from damaged cells
Activates neutrophils and monocytes
Surgery will expose the Subendothelium = coagulation stimulation
Platelet activation
Vascular endothelial cell activation
mechanical bleeding causes
- surgical leak
Insufficient fibrin formation
- thrombin inhibition
- insufficient fibrinogen
- insufficient thrombin generation
insufficient clot integrity
- insufficient fibrin formation
- insufficient fibrinogen
- insufficient thrombin generation
- platelet dysfunction
- insufficient platelet number
insufficient clot adhesion
- insufficient GPIb function
- insufficient vWf
fibrinolysis
- Primary: pathological plasmin
- secondary: physiological plasmin